| Matthew E Price, MD | |
|
300 S 8th St Ste 203e, Murray, KY 42071-2400 | |
| (270) 762-1562 | |
| (270) 752-2864 |
| Full Name | Matthew E Price |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 21 Years |
| Location | 300 S 8th St Ste 203e, Murray, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528118551 | NPI | - | NPPES |
| 7100006560 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 41025 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Murray-calloway County Hospital | Murray, KY | Hospital |
| Scripps Memorial Hospital La Jolla | La jolla, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Murray-calloway County Public Hospital Corporation | 0840103297 | 73 |
News Archive
Affinium Pharmaceuticals announced today the closing of its $15 million financing. Investors participating in the financing include all three of Affinium's Series A investors, SV Life Sciences, Genesis Capital Partners and Forward Ventures, along with the addition of the Ontario Emerging Technologies Fund (OETF) to the syndicate.
What's in a name? Doctors have found that the name of the drug you are prescribed significantly influences how the patient sees the treatment.
W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-FXIRx. The results demonstrated that treatment with ISIS-FXIRx produced dose-dependent statistically significant reductions of up to 78 percent in Factor XI activity.
› Verified 1 days ago
| Entity Name | Murray-calloway County Public Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629202858 PECOS PAC ID: 0840103297 Enrollment ID: O20040429001328 |
News Archive
Affinium Pharmaceuticals announced today the closing of its $15 million financing. Investors participating in the financing include all three of Affinium's Series A investors, SV Life Sciences, Genesis Capital Partners and Forward Ventures, along with the addition of the Ontario Emerging Technologies Fund (OETF) to the syndicate.
What's in a name? Doctors have found that the name of the drug you are prescribed significantly influences how the patient sees the treatment.
W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-FXIRx. The results demonstrated that treatment with ISIS-FXIRx produced dose-dependent statistically significant reductions of up to 78 percent in Factor XI activity.
› Verified 1 days ago
| Entity Name | Primary Care Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295716694 PECOS PAC ID: 7618919838 Enrollment ID: O20050527000431 |
News Archive
Affinium Pharmaceuticals announced today the closing of its $15 million financing. Investors participating in the financing include all three of Affinium's Series A investors, SV Life Sciences, Genesis Capital Partners and Forward Ventures, along with the addition of the Ontario Emerging Technologies Fund (OETF) to the syndicate.
What's in a name? Doctors have found that the name of the drug you are prescribed significantly influences how the patient sees the treatment.
W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-FXIRx. The results demonstrated that treatment with ISIS-FXIRx produced dose-dependent statistically significant reductions of up to 78 percent in Factor XI activity.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew E Price, MD 1000 S 12th St, Murray, KY 42071-9303 Ph: (270) 759-9200 | Matthew E Price, MD 300 S 8th St Ste 203e, Murray, KY 42071-2400 Ph: (270) 762-1562 |
News Archive
Affinium Pharmaceuticals announced today the closing of its $15 million financing. Investors participating in the financing include all three of Affinium's Series A investors, SV Life Sciences, Genesis Capital Partners and Forward Ventures, along with the addition of the Ontario Emerging Technologies Fund (OETF) to the syndicate.
What's in a name? Doctors have found that the name of the drug you are prescribed significantly influences how the patient sees the treatment.
W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-FXIRx. The results demonstrated that treatment with ISIS-FXIRx produced dose-dependent statistically significant reductions of up to 78 percent in Factor XI activity.
› Verified 1 days ago
Dawn Deeter, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 300 S 8th St Ste 178w, Murray, KY 42071 Phone: 270-762-1563 Fax: 270-752-2865 | |
Rebecca Jane Craig, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 300 S 8th St Ste 203e, Murray, KY 42071 Phone: 270-762-1792 Fax: 270-767-1783 | |
Ellen Burnett, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 305 S 8th St, Murray, KY 42071 Phone: 270-753-9300 Fax: 270-753-2413 | |
Karla Roy Turley, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 300 S 8th St Ste 203e, Murray, KY 42071 Phone: 270-762-1562 Fax: 270-752-2864 | |
Thomas Green, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 305 S 8th St, Murray, KY 42071 Phone: 270-753-9300 Fax: 270-753-3549 |